ASND vs ACAD

For growth investors, Ascendis Pharma A/S (ASND) is the stronger pick with 90.

2% revenue growth year-over-year, versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 4x trailing P/E (48. 5x forward), making it the more compelling value choice. Analysts rate Ascendis Pharma A/S (ASND) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, ACADIA Pharmaceuticals Inc.

is actually cheaper at 48. 5x.

Over the past 5 years, Ascendis Pharma A/S (ASND) delivered a total return of +77.

5%, compared to +2. 5% for ACADIA Pharmaceuticals Inc. (ACAD). Over 10 years, the gap is even starker: ASND returned +1367% versus ACAD's -22. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ascendis Pharma A/S (ASND) is the lower-risk stock at 0.

33β versus ACADIA Pharmaceuticals Inc. 's 1. 26β — meaning ACAD is approximately 282% more volatile than ASND relative to the S&P 500.

By revenue growth (latest reported year), Ascendis Pharma A/S (ASND) is pulling ahead at 90.

2% versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to 44. 6% for Ascendis Pharma A/S. Over a 3-year CAGR, ASND leads at 138. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -31. 7% for Ascendis Pharma A/S — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -18. 9% for ASND. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ACADIA Pharmaceuticals Inc.

(ACAD) trades at 48. 5x forward P/E versus 59. 2x for Ascendis Pharma A/S — 10. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACAD: 61. 9% to $34. 78.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ascendis Pharma A/S (ASND) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

33), +1367% 10Y return). Both have compounded well over 10 years (ASND: +1367%, ACAD: -22. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ASND is a mid-cap high-growth stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.